
Accurately diagnosing all stages and types of cancer from patient biopsies is not currently possible. Tests built upon existing technologies are nowhere near the sensitivity or specificity required to be of practical use. Wobble has developed novel RNA biochemistry that has the potential to radically and economically improve diagnostics, democratising affordable, accurate tests to improve patient outcomes.